Esketamine Interaction Study in Healthy Volunteers: A Clinical Trial Evaluation

The primary objective of the KF2024#1 trial, titled "Esketamine interaction study," is to evaluate the **interaction** of Esketamine in **healthy volunteers**. This study is clinically relevant as it aims to understand the pharmacokinetic and pharmacodynamic interactions of Esketamine, which is crucial for ensuring its safe and effective use in clinical settings. No secondary objectives are provided for this trial.

The clinical trial involves **healthy volunteers** as the study population, with both male and female participants included. The age range of participants is categorized as adults, although the specific age range is not provided. The sponsor has not disclosed the total number of participants involved in the trial. The selection process for the trial population is not detailed, and there is no information regarding specific lifestyle considerations such as diet, physical activity, or habits. The study does not focus on a vulnerable population, and no significant inclusion or exclusion criteria have been highlighted by the sponsor.

The clinical trial is designed as a **randomized**, double-blind, controlled study involving **healthy volunteers**. The trial is categorized under Phase 2 and aims to evaluate the interaction of **esketamine**. The estimated recruitment start date is September 1, 2024, with an anticipated completion by December 31, 2025. Participants will be involved in the study for a duration that aligns with the trial's timeline, subject to their continued eligibility and adherence to the study protocol.

The sequence of study visits begins with an inclusion visit, also known as the screening visit, where potential participants are assessed for eligibility based on predefined criteria. This visit ensures that only suitable candidates are enrolled in the trial. Following successful screening, participants will undergo a series of follow-up visits at specified intervals. These visits are crucial for monitoring the participants' health, assessing the effects of the intervention, and ensuring compliance with the study protocol. The trial will conclude with an end-of-study visit, where final assessments are conducted to gather comprehensive data on the study's outcomes.

Participants are expected to remain in the study for its entire duration unless specific conditions necessitate early termination. Such conditions may include adverse reactions, non-compliance with the study protocol, or withdrawal of consent. The trial's design and procedures are structured to maintain scientific rigor and ensure the safety and well-being of all participants throughout the study period.

In this clinical trial, the experimental medication and non-experimental treatments have not been specified in the provided data. Therefore, a detailed description of the **experimental medication**, including its name, pharmaceutical form, dosage, route, and frequency of administration, cannot be provided. Similarly, information regarding any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, is not available.

Due to the lack of specific information, additional relevant details about drug administration, dosing schedules, and participant compliance monitoring are also not included. The absence of data on the **experimental medication** and non-experimental treatments limits the ability to provide a comprehensive description of the treatments used in this clinical trial.

The clinical trial is designed to assess efficacy in a Phase 2 study. The trial is scheduled to commence recruitment on September 1, 2024, with an estimated completion date of December 31, 2025. Efficacy will be evaluated using specific parameters or endpoints, although these are not detailed in the provided data. The trial will follow a structured methodology for measuring, collecting, and analyzing these efficacy parameters, adhering to the standards expected in Phase 2 clinical trials. The trial's design and execution will ensure that the efficacy assessments are conducted systematically and objectively, in line with clinical trial protocols.